| Similar Articles |
|---|
 |
The Motley Fool
August 31, 2004
Charly Travers |
Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one.   |
The Motley Fool
May 31, 2005
Karl Thiel |
Is Eyetech Better Than It Looks? If you're a born contrarian with a little spare mad money lying around, this biotech could be worth buying at these levels. |
The Motley Fool
January 3, 2005
Rich Duprey |
Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA. |
The Motley Fool
January 21, 2005
Charly Travers |
Seeing the Value in QLT A narrow-minded market could be creating a great drug value. |
The Motley Fool
August 22, 2005
Rich Duprey |
Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies. |
The Motley Fool
February 11, 2005
Stephen D. Simpson |
For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant. |
The Motley Fool
April 25, 2005
Charly Travers |
Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around? |
The Motley Fool
May 24, 2005
Charly Travers |
Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note. |
BusinessWeek
August 16, 2004
Arlene Weintraub |
The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near. |
The Motley Fool
May 25, 2005
Tom Taulli |
Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note. |
The Motley Fool
February 23, 2005
Charly Travers |
QLT Is Still a Value The market's concerns mean this Canadian drug company is being offered up at a great price. |
The Motley Fool
January 5, 2005
Rich Duprey |
Sharks Don't Go Blind Shark liver oil shows promise in treatment of age-related macular degeneration. Genaera Corp. though leading this interesting investigation, is not profitable, racking up some significant losses over the years. |
The Motley Fool
September 16, 2008
Brian Lawler |
Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site. |
The Motley Fool
February 27, 2007
Billy Fisher |
OSI Eyeing Growth in '07 Despite recent mixed results, the pharmaceutical has higher hopes for the year. Investors, take note. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
Managed Care
March 2005
Thomas Morrow |
Aptamers: Slowing Progression of AMD A single strand of nucleic acid may hold the key to treating the leading cause of severe vision loss and blindness resulting from age-related macular degeneration. |
The Motley Fool
October 15, 2007
Brian Lawler |
Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note. |
The Motley Fool
February 22, 2005
Charly Travers |
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. |
The Motley Fool
March 29, 2005
Charly Travers |
A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Pfizer Fosters Fertile Future Results in the "here and now" aren't bad, but it will take a couple of years to build growth. Of course, investors must do their own research and make their own decisions. |
Fast Company
May 2004
Ryan Underwood |
Fast Talk: Now Hiring At a time when all of corporate America seems to be doing more with less, we found a few companies, big and small, that are actually staffing up. So we had to ask: Why are you hanging out the "Help Wanted" sign? |
The Motley Fool
February 22, 2007
Ryan Fuhrmann |
Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008. |
